Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. (2015)

Peer-Reviewed Study · Ren-Yuan Bai; Verena Staedtke; Charles M Rudin et al. · April 2015

Ren-Yuan Bai et al., 2015-04: Medulloblastoma study testing mebendazole across three orthotopic models of different molecular background, including a vismodegib-resistant tumour, with survival and angiogenesis endpoints.

Mice bearing orthotopic PTCH1-mutant medulloblastoma allografts, a group 3 medulloblastoma xenograft, and a PTCH1-mutant medulloblastoma with acquired resistance to the smoothened inhibitor vismodegib were treated with MBZ.

Ren-Yuan Bai et al., 2015-04: Medulloblastoma study testing mebendazole across three orthotopic models of different molecular background, including a vismodegib-resistant tumour, with survival and angiogenesis endpoints. Study type: orthotopic mouse allograft and xenograft medulloblastoma models. N: not stated in the abstract. Country: USA (Johns Hopkins). Dose/route/schedule: not stated in the abstract text captured. Funder: US NIH P30 CA008748, R01 CA157535. Declared conflicts: no COI statement in the record. Comparator: untreated tumour-bearing mice; vismodegib resistance as a model feature. Also filed as MBB-18 (claims C3, C5). Study type: animal.